Brought to you by 
Millennium acquires LeukoSite for $585mm
09 May 2001
Executive Summary
Millennium Pharmaceuticals has acquired LeukoSite (cancer, autoimmune, and inflammatory disease therapeutics) for about $585mm. Millennium has issued common stock worth about $33 (0.43 share) for each LeukoSite share; that's a (pr)62% premium to LeukoSite's market average.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Intra-Biotech Deal
- Payment Includes Stock
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com